S
Shoreline Biosciences
Developing clinically effective immunotherapies using intelligently engineered iPSC-derived allogeneic cells
About Shoreline Biosciences
Shoreline Biosciences is a biotechnology startup that is pioneering the development of next-generation cellular immunotherapies. The company operates in the healthcare sector, specifically in the field of cancer treatment. Shoreline Biosciences is focused on creating innovative therapies using induced pluripotent stem cell (iPSC)-derived natural killer (iNK) cells and macrophages (iMACs). In simple terms, iPSCs are a type of stem cell that can be generated directly from adult cells and have the potential to differentiate into various types of cells, including iNK and iMACs, which play a crucial role in the immune response.
Read full description
The company serves a broad range of clients, primarily patients in need of novel cancer treatments. Their business model revolves around leveraging their deep expertise in iPSC differentiation, genetic engineering, and immune cell biology to develop new cellular immunotherapies. These therapies are designed to be safe, effective, and affordable, offering a promising alternative to traditional cancer treatments.
Shoreline Biosciences generates revenue by developing and commercializing these innovative therapies. Their approach allows them to create homogenous and scalable off-the-shelf products, which can be mass-produced and readily available for patients, thereby increasing the potential for significant revenue generation.
At a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- San Diego, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 60.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Shoreline Biosciences.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Nov 2021 | $140M | $560M | Kite Pharma · Eventide Asset Management · Kingdon · BeOne Medicines | ↗ |
| EARLY VCOther financing | Apr 2021 | $43M | $172M | Kite Pharma · Wedbush Morgan Securities · BVF Partners · Janus Henderson Investors | — |
Growth signals
Latest recorded traffic for Shoreline Biosciences is 1.7K monthly website visits, down 99.7% over the last three months. Shoreline Biosciences's team declined 57.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A9 investors entered at this stage
Kite Pharma
Wedbush Morgan Securities
BVF Partners
Janus Henderson Investors
Logos Capital
Commodore Capital
Boxer Capital- CCCormorant Capital
Stork Capital
Series B and later9 investors entered at this stage
Ally Bridge Group
Eventide Asset Management
Kingdon
BeOne Medicines- PCPiper Heartland Healthcare Capital
Cormorant Asset Management- IIIrving Investors
- TCTimefolio Capital
Superstring
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shoreline Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shoreline Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.